Ginkgo Bioworks Holdings, Inc.
In the quarter to June 2026, revenue fell 48.5%, EPS grew 31.8% and free cash flow fell 16.4%, each against the same quarter a year earlier.
Follow DNA
Ginkgo Bioworks Holdings, Inc. (DNA) EV/Sales
As of 16 October 2026, Ginkgo Bioworks Holdings, Inc. (DNA) trades at a EV/Sales of 3.0×. Over the past ten years it has ranged from −2.1× (September 2024) to 101× (November 2021); the current reading is higher than 54% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.6× | 1,561.10% |
| FY2024 | 0.0× | (99.63%) |
| FY2023 | 9.4× | 221.34% |
| FY2022 | 2.9× | (90.61%) |
| FY2021 | 31.1× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.8× | 728.04% |
| Mar 2026 | 0.3× | (40.98%) |
| Dec 2025 | 0.6× | (77.45%) |
| Sep 2025 | 2.6× | 164.35% |
| 19 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SANA Sana Biotechnology, Inc. compare | n/m |
| HELP Cybin Inc. compare | n/m |
| CRVS Corvus Pharmaceuticals, Inc. compare | n/m |
| AVBP ArriVent BioPharma, Inc. compare | n/m |
| ARDX Ardelyx, Inc. compare | 1.7× |
| DNA Ginkgo Bioworks Holdings, Inc. | 3.0× |
| GERN Geron Corporation compare | 3.3× |
| VSTM Verastem, Inc. compare | 9.3× |
| ALMS Alumis Inc. compare | 37.7× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)